Back to Feed
ClinicalTrials.gov|Clinical Trial
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Janssen Research & Development, LLC
Abstract
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528. Phase: PHASE2 Status: ACTIVE_NOT_RECRUITING Conditions: Multiple Myeloma Interventions: JNJ-68284528; Lenalidomide; Daratumumab; Bortezomib; Dexamethasone
Keywords
Multiple Myeloma